Clinical Trial Update: BRL49653C In Type 2 Diabetes -Comparison Study With Pioglitazone And Placebo By Monotherapy- [Phase 3]

View source ↗

Summary

Phase 3 trial update comparing BRL49653C monotherapy to pioglitazone and placebo in type 2 diabetes (completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• BRL49653C
• PIOGLITAZONE (Pioglitazone)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED